Briefing history

The oral GLP-1 market is rapidly maturing as Novo Nordisk leverages its commercial lead over Eli Lilly's newly launched Foundayo to…

The commercial obesity market is intensifying as the battleground expands from injectable volume to oral market share and legal arenas.

The commercial obesity market is shifting from a battle over injectable market share to a high-stakes race for oral dominance and…

The race for cardiometabolic dominance is fracturing along clinical and legal fault lines as developers look beyond traditional…

The GLP-1 landscape is transitioning from a clinical land grab into a high-stakes legal and generic defense battle.

The GLP-1 commercial landscape is undergoing a sharp polarization: while manufacturers are successfully expanding oral options globally,…

The obesity therapeutics market is entering a new phase of clinical and operational maturity as federal programs step in to subsidize…

The obesity therapeutics market is rapidly pivoting toward oral formulations following the FDA approval of Eli Lilly’s Foundayo…

The commercial landscape for obesity medications is undergoing a sharp structural split as private employers aggressively scale back…

The race for a viable third-place position behind the Eli Lilly and Novo Nordisk duopoly is undergoing a massive paradigm shift as…

Eli Lilly has captured the commercial upper hand in the United States through a major CVS Caremark formulary expansion, even as Novo…

The GLP-1 economy is moving past pure retail competition as major pharmacy benefit managers and federal policy interventions rapidly expand…

The GLP-1 landscape is undergoing a massive shift from weekly injections to flexible daily oral pills and extended monthly dosing.